Sanofi: Breakthrough Therapy Designation for venglustat in the United States

Sanofi announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to venglustat, an oral treatment for type 3 Gaucher disease. This rare disease is caused by an enzyme deficiency leading to lysosomal storage, with progressive neurological symptoms. The designation is based on results from the Phase 3 LEAP2MONO study, which demonstrated an improvement in neurological symptoms in patients treated with venglustat compared to standard enzyme replacement therapy.

Sanofi emphasizes that venglustat has not revealed any new significant side effects compared to previous studies. Commonly observed adverse effects include headaches and nausea. Already designated a "fast-track" and "orphan drug," venglustat continues its development, highlighting the need for innovative solutions for neurological symptoms associated with MG3.